Recursion Pharmaceuticals, Inc. RXRX Restricted Cash
Restricted Cash at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCashCurrent.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s restricted cash?
- Recursion Pharmaceuticals, Inc. (RXRX) reported restricted cash of $5.51M in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s restricted cash changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s restricted cash increased by 79.2% year-over-year, from $3.08M to $5.51M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s restricted cash?
- Over 5 years (2020 to 2025), Recursion Pharmaceuticals, Inc.'s restricted cash has grown at a 18.1% compound annual growth rate (CAGR), from $2M to $4.59M.
- What does restricted cash mean?
- Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.